Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Revatis logo — An innovative patented and minimally invasive approach for o...

Revatis

An innovative patented and minimally invasive approach for obtaining stem cells

Founded 2013 Belgium Belgium 14 employees Biotechnology, Health Care

General Information

Company Name Revatis
Founded Year 2013
Location Belgium Belgium
Employees 14
Industries Biotechnology, Health Care
Social

BounceWatch is an independent company data service, not affiliated with Revatis. To contact Revatis, visit revatis.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

New Partnership Sep 15, 2026

Revatis has a partnership with BioWin, an innovation cluster, as a member of their biotech and health innovation ecosystem, which led to Revatis being showcased in the BioWin Morning Club series.

Certification Sep 15, 2026

Revatis has achieved GMP compliance for its stem cell manufacturing capabilities, demonstrating its ability to meet rigorous quality standards for potential clinical applications.

Regulatory Approval Sep 02, 2026

Revatis has received authorization from the FAMHP (Belgian medicines agency) for a clinical study evaluating Exovet RLC100 for the treatment of keratitis in horses.

Get alerts when Revatis shows new signals

About Revatis

Revatis, founded in 2013 , is revolutionizing biomedical technology with its innovative patented approach for obtaining stem cells . The company's focus on research and development is evident through its commitment to delivering practical solutions that address real-world healthcare challenges. The patented technology for obtaining multipotent stem cells from muscle micro-biopsies represents a significant breakthrough in regenerative medicine . These stem cells have the potential to address various medical issues, from tissue repair to immune modulation, in both veterinary and human applications. Moreover, Revatis is not only limited to its current achievements but is continuously exploring new avenues, including extracellular vesicle production , 3D cell culture using platelet lysates , and proprietary enzymatic reagents for cell release. These efforts are aimed at developing practical, effective solutions that can improve patient outcomes. The company's collaboration with leading institutions and experts is central to its approach, leveraging collective expertise to accelerate the development and adoption of innovative therapies. Based in Belgium , Revatis is truly at the forefront of driving progress in biomedical technology. As an investor, it’s exciting to see the potential for this innovative approach to significantly impact the healthcare industry and patient outcomes. With its dedication to research, practicality, and collaboration, Revatis presents an enticing opportunity for those looking to support advancements in regenerative medicine and biomedical solutions. Therefore, it would be intriguing to monitor any future developments and potential investments in this promising company.

Taxonomy: Biomedical Technology, Regenerative Medicine, Stem Cell Research, Innovative Therapies, Medical Innovations, Cell Therapy, Extracellular Vesicles, 3D Cell Culture, Tissue Repair, Immune Modulation, Collaborative Partnerships, Patented Technology, Minimally Invasive Procedures

No funding data available for Revatis yet.

Revatis Alternatives & Competitors

Revatis vs
Aglaris Ltd Group
Aglaris Ltd Group United Kingdom

Aglaris Ltd. together with Aglaris Cell, Changing Cellular Manufacturing: More productive, more reli...

Grant
11 employees
Biotechnology, Health Care
Revatis vs
PrimeCell Bioscience, a.s.
PrimeCell Bioscience, a.s. Czech Republic

Měníme klasické paradigma léčby

4 employees
Biotechnology, Health Care
Revatis vs
Aptus Bioreactors
Aptus Bioreactors United States

Regenerating Tissues, for Life

3 employees
Biotechnology, Health Care

FAQ About Revatis

An innovative patented and minimally invasive approach for obtaining stem cells
Revatis was founded in 2013.
Revatis is headquartered in Belgium.
Revatis operates in Biotechnology and Health Care. Its work centres on Biomedical Technology, Regenerative Medicine, Stem Cell Research and Innovative Therapies.
Revatis has approximately 14 employees.
Top alternatives and competitors to Revatis include Aglaris Ltd Group, PrimeCell Bioscience, a.s., Aptus Bioreactors, InGeneron, StemSight - Vision Unlimited. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Revatis and Aglaris Ltd Group are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Revatis, https://bouncewatch.com/company/revatis, updated 25 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes